Obihiro University of Agriculture and Veterinary Medicine

www.obihiro.ac.jp
Obihiro, Japan

Obihiro University of Agriculture and Veterinary Medicine is a university in Obihiro, Hokkaido, Japan. Commonly referred to as Obihiro University, it is the only national university of agriculture and veterinary medicine in Japan. It was founded in 1941 as the Obihiro Technical School of Veterinary Medicine.As of 2009, the university employs 136 faculty members and a full-time staff of over 100. It offers instruction to 1,300 students in bachelors, masters, and doctoral programs. The university accepts an average of 14 foreign students and sends out an average of seven study abroad students each year. Wikipedia.


Time filter

Source Type

Patent
Obihiro University of Agriculture, Veterinary Medicine and Chugai Seiyaku Kabushiki Kaisha | Date: 2010-01-13

Compositions for protecting transplanted organs, promoting survival of transplanted organs or preserving organs for transplant containing erythropoietin (EPO) as an active ingredient are provided.


Patent
Idemitsu Kosan Co., Nara Institute of Science, Technology, Obihiro University of Agriculture and Veterinary Medicine | Date: 2010-03-31

A technology for producing a pig edema disease vaccine at low cost and at high efficiency is developed. Specifically, a gene of a pig edema disease toxin protein (Stx2e protein) is efficiently expressed in plant cells to produce a plant vaccine for pig edema disease at low cost. An Stx2e protein including a secretory signal peptide derived from a plant added at an amino terminus is expressed in cells of a plant such as Lactuca sativa using the 5-untranslated region of an alcohol dehydrogenase gene (ADH5UTR) derived from a plant.


Patent
Incorporated Administrative Agency National Agriculture And Food Research Organization, Obihiro University of Agriculture and Veterinary Medicine | Date: 2010-09-30

A method for producing an -Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an -Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an -galactose epitope (Gal1-3Gal1-4GlcNAc-R: -Gal hereinafter)-expressing virus, which comprises the steps of: (1) introducing an 1,3- galactosyltransferase gene in an expressible condition into a cell line that does not express -Gal to obtain a cell line capable of expressing -Gal; (2) inoculating a virus into the cell line capable of expressing -Gal to obtain a cell line infected with a virus; and (3) culturing the cell line infected with the virus to obtain a virus expressing -Gal from the culture medium..


Patent
Obihiro University of Agriculture, Veterinary Medicine, Incorporated Administrative Agency National Agriculture and Food Research Organization | Date: 2012-08-08

A method for producing an -Gal-expressing virus having enhanced immune response to viruses, without requiring the use of any enzyme; an influenza virus vaccine having a high effect (antigenicity), which is produced using an -Gal-expressing virus produced by the method; and others. Specifically disclosed are: a method for producing an -galactose epitope (Gal1-3Gal1-4GlcNAc -R: -Gal hereinafter)-expressing virus, which comprises the steps of:(1) introducing an 1,3-galactosyltransferase gene in an expressible condition into a cell line that does not express -Gal to obtain a cell line capable of expressing -Gal;(2) inoculating a virus into the cell line capable of expressing -Gal to obtain a cell line infected with a virus; and(3) culturing the cell line infected with the virus to obtain a virus expressing -Gal from the culture medium.


Patent
Obihiro University of Agriculture, Veterinary Medicine and Nihon Plast Co. | Date: 2014-12-04

The purpose of the present invention is to provide a novel urethane decomposing method by which urethane in the environment is treated efficiently and at a low cost, and a urethane decomposing agent. The above purpose is attained by employing a urethane decomposing method including: a step of treating a urethane-containing material to be treated using an unsaturated fatty acid; and a step of making a microorganism belonging to a Streptomyces genus and exhibiting urethane decomposing function, to act on the material treated using the unsaturated fatty acid.


Patent
Obihiro University of Agriculture, Veterinary Medicine and Waseda University | Date: 2011-03-10

The object is to develop an antiprotozoal remedy having a novel mechanism of action. Provided is a compound represented by a chemical formula (1), a prodrug or a pharmaceutically acceptable salt thereof, wherein within the formula (1), R_(1 )represents R_(10) of formula (4) or R_(20) of formula (5); R_(2 )represents CHO, etc.; R_(3 )represents a hydrogen atom, CH_(3)C(O), etc.; R_(4 )represents a hydrogen atom, CH_(3)C(O), etc.; each of R_(11 )and R_(12 )independently represents each a hydrogen atom, a methyl group, etc.; R_(13 )represents CH_(2), CH(OH) or C(O); each of R_(21 )and R_(22 )independently represents eaeh a hydrogen atom, a methyl group, etc.; R_(23 )represents CH_(2), CH(OH) or C(0); and R_(24 )represents a hydrogen atom, a hydroxyl group, a methyl group, etc.


Patent
Waseda University, Obihiro University of Agriculture and Veterinary Medicine | Date: 2013-01-16

The object is to develop an antiprotozoal remedy having a novel mechanism of action. Provided is a compound represented by a chemical formula (1), a prodrug or a pharmaceutically acceptable salt thereof, wherein within the formula (1), R_(1) represents R_(10)- of formula (4) or R_(20)- of formula (5); R_(2) represents CHO-, etc.; R_(3) represents a hydrogen atom, CH_(3)-C(=O)-, etc.; R_(4) represents a hydrogen atom, CH_(3)-C(=O)-, etc.; each of R_(11) and R_(12) independently represents a hydrogen atom, a methyl group, etc.; R_(13) represents -CH_(2)-, -CH(-OH)- or -C(=O)-; each of R_(21) and R_(22) independently represents a hydrogen atom, a methyl group, etc.; R_(23) represents -CH_(2)-, -CH(-OH)- or -C(=O)-; and R_(24) represents a hydrogen atom, a hydroxyl group, a methyl group, etc.


Okamoto M.,Obihiro University of Agriculture and Veterinary Medicine | Dan I.,Jichi Medical University
Seminars in Cell and Developmental Biology | Year: 2013

The perception of taste and flavor can be greatly biased by extrinsic cues, or the information about a food that comes from outside of the food itself, such as package designs, brands, prices, and so on. In order to understand taste/flavor experiences in a broader context, it is necessary to consider factors other than the food/tastants themselves. This review aims to summarize some of the relevant findings from psychological and neuroimaging studies, focusing on depicting how extrinsic cues exert their effect on taste and flavor. Currently, the most frequently considered psychological mediator for the effects of extrinsic cues is expectation. Depending on the gap between expectation and taste/flavor experience, four major models predict outcomes of expectation effects: (1) assimilation, (2) generalized-negativity, (3) contrast, and (4) assimilation-contrast. Among them, the most influential is the assimilation model proposing that taste/flavor experiences are modified toward what one expects. Thus far, all the neuroimaging studies examining the influence of extrinsic cues have dealt with assimilation effects. They suggest that when extrinsic cues influence taste/flavor perception, cortical representations of taste/flavor are also modulated. Collectively neuroimaging findings partly answer questions arising from psychological aspects: the influence of extrinsic cues is not due to superficial response bias but to truly changed perception. These findings, albeit limited to assimilation effects, suggest that combined understanding from both psychological and neuroimaging studies would help deepen our understanding of the taste experience. © 2012.


Miyamoto A.,Obihiro University of Agriculture and Veterinary Medicine
Society of Reproduction and Fertility supplement | Year: 2010

Development of the corpus luteum (CL) in ruminants occurs in a rapid and time-dependent manner within 1 week after ovulation, with morphologic and biochemical changes in the cells of the theca interna and granulosa cells of the preovulatory follicle. These changes involve luteinisation of steroidogenic cells and angiogenesis to establish normal luteal function (progesterone secretion). The CL is composed of a large number of vascular endothelial cells, large and small steroidogenic luteal cells, smooth muscle cells, pericytes, fibrocytes and immune cells, indicating that the CL is a heterogeneous tissue. Moreover, the CL produces and secretes growth factors (fibroblast growth factor, vascular endothelial growth factor and insulin-like growth factor), vasoactive factors (nitric oxide, angiotensin II and endothelin-1), steroids (progesterone is important for its own production), oxytocin and prostaglandins (PGF2alpha and PGE2) to regulate luteal formation and development. Clearly, the main function of the CL is to produce progesterone, which is a prerequisite for survival of the embryo, implantation and maintenance of pregnancy. Inadequate luteinisation and angiogenesis during the early luteal phase results in poor progesterone secretion and causes compromised embryo development and reduced fertility. Secretion of adequate amounts of progesterone during luteal development requires "precise luteinisation" of theca and granulosa cells to form luteal cells, neovascularization, and the establishment of a blood supply (angiogenesis). PGF2alpha in the developing CL acts as a local regulator to enhance progesterone secretion directly and indirectly by stimulating angiogenic factors, VEGF and FGF2. The preceding role of PGF2alpha may explain why the developing CL does not acquire luteolytic capacity until several days following ovulation. The balance between luteotrophic and luteolytic factors as well as stimulation and inhibition of angiogenic factors during luteal formation, development and maintenance can have a profound effect on the fate of the CL.


Patent
Obihiro University of Agriculture and Veterinary Medicine | Date: 2015-07-01

The present invention relates to a vaccine formulation against Toxoplasma gondii infection. More specifically, the invention relates to a vaccine formulation in which a Toxoplasma gondii-derived soluble protein is included in liposomes each having an oligosaccharide capable of binding to a carbohydrate recognition molecule on the surface of antigen-presenting cells on the surface of the liposome.

Loading Obihiro University of Agriculture and Veterinary Medicine collaborators
Loading Obihiro University of Agriculture and Veterinary Medicine collaborators